Masimo Co. (NASDAQ:MASI) Receives $194.80 Consensus Price Target from Brokerages

Masimo Co. (NASDAQ:MASI) has received a consensus recommendation of “Moderate Buy” from the six analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $194.80.

A number of research analysts have issued reports on the stock. Raymond James boosted their price objective on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research report on Friday, December 27th. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Wednesday, February 26th. Wells Fargo & Company boosted their price objective on shares of Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Finally, Piper Sandler boosted their target price on shares of Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th.

Masimo Stock Down 2.2 %

Shares of NASDAQ MASI opened at $165.82 on Monday. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. Masimo has a 52 week low of $101.61 and a 52 week high of $194.88. The firm’s fifty day moving average is $174.99 and its 200 day moving average is $159.82. The company has a market cap of $8.95 billion, a price-to-earnings ratio of 114.36 and a beta of 1.04.

Masimo (NASDAQ:MASI) last issued its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, topping the consensus estimate of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company had revenue of $600.70 million for the quarter, compared to the consensus estimate of $593.35 million. On average, equities research analysts expect that Masimo will post 4.1 earnings per share for the current year.

Insider Buying and Selling at Masimo

In other news, COO Bilal Muhsin sold 30,000 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the completion of the sale, the chief operating officer now owns 24,172 shares of the company’s stock, valued at $4,048,568.28. This represents a 55.38 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Craig B. Reynolds sold 2,053 shares of the company’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the sale, the director now directly owns 16,581 shares of the company’s stock, valued at $2,754,601.53. The trade was a 11.02 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 9.70% of the company’s stock.

Institutional Investors Weigh In On Masimo

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MASI. Jones Financial Companies Lllp purchased a new stake in Masimo in the 4th quarter worth approximately $27,000. UMB Bank n.a. boosted its position in shares of Masimo by 180.9% during the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock valued at $32,000 after acquiring an additional 123 shares during the last quarter. Trust Co. of Vermont bought a new position in shares of Masimo during the 4th quarter valued at approximately $33,000. Blue Trust Inc. boosted its position in shares of Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 71 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Masimo by 40.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock valued at $37,000 after acquiring an additional 64 shares during the last quarter. 85.96% of the stock is owned by hedge funds and other institutional investors.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.